生意编号38870
最近更新2025年09月02日
2727人已浏览
An Unparalleled Investment Opportunity
东海岸居家护理医疗用品制药厂
转让费S$10万
生意转让
寻求投资
合作伙伴
生意概述
- 物业类型 一
- 物业面积 一
- 每月租金 一
- 房租押金 一
- 月营业额 一
- 欠款负债 一
- 月毛利润 一
- 月净利润 一
- 库 存 一
- 设施设备 一
- 应付帐款 一
- 应收账款 一
- 卖家职责 投资者
- 员工人数 8
- 成立时间 2018
- 发布来源 个人
转让原因
expanding
生意详情
An Unparalleled Investment Opportunity: CAVADEX® and the Billion-Dollar Inflection Point.
Cardiovascular Disease (CVD) is the world’s #1 killer, affecting over 620 million people globally. For decades, the medical industry’s best defense—statins—has only managed symptoms and slowed progression.
Cholrem Pty Ltd has shattered the status quo.
We introduce CAVADEX®, a groundbreaking, scientifically validated therapy that doesn't just treat heart disease—it reverses it.
Validated by a landmark peer-reviewed study published in Cardiology Research and Cardiovascular Medicine (August 2025), CAVADEX® actively dissolves arterial plaque and dangerous cholesterol crystals at the source.
"It's the greatest advance that we have had in cardiovascular pharmacology... since the statins came on the scene." — Professor Laurie Howes, MB BS PhD FRACP FCSANZ (40+ years in Cardiovascular Pharmacology)
A De-Risked Pathway to a Trillion-Dollar Market
This is not a typical early-stage biotech investment. Cholrem is not navigating years of R&D uncertainty. We are a revenue-generating company with a proven product, positioned for exponential growth.
• Proven Human Efficacy: Real-world data and pilot studies demonstrate a remarkable 92% success rate in plaque regression.
• Established Revenue: CAVADEX® has been in production and selling worldwide for over five years.
• Safety Assured: The active ingredient is already FDA-approved (GRAS) with a long-established, non-toxic safety profile.
• Immediate Scalability: Robust, proven manufacturing infrastructure capable of immediately scaling to $25 Million USD in weekly revenue from a single site.
The Catalyst: Formal Clinical Trials
We are at a critical inflection point. We are seeking strategic capital to initiate accelerated clinical trials. The final step to validate our extensive real-world evidence and unlock global market dominance.
These aren’t just any trials, we are going for the Holy Grail of trials. Calcium scores are the leading indicator of heart disease and, until now, have been considered irreversible. No existing therapy can reduce them. We will show calcium scores plummeting within 3 months. We know this because we are seeing it every day from customers using Cavadex.
The commencement of these 3 month trials, scheduled for early November 2025, will serve as a massive commercial catalyst.
Given the proven efficacy and the scale of the addressable market (capturing just 10% of the U.S. market projects revenues exceeding $3.15 billion USD per MONTH!), we project this milestone will elevate Cholrem to a billion-dollar valuation.
The Opportunity
We are offering equity in Cholrem Pty Ltd for this pivotal, limited funding round.
$100,000 per 1% share. Limited round up to $2 million (20% equity) to fund trials and ignite global dominance.
This is a rare opportunity to generate exceptional returns while funding the most significant revolution in cardiovascular health in a generation.
Own a substantial equity share in a potentially multibillion-dollar company.
Request the Business Brief and scientific documentation today.
Visit: www.cholrem.com
Contact: Kyle Hodgetts,
Founder & CEO
Cardiovascular Disease (CVD) is the world’s #1 killer, affecting over 620 million people globally. For decades, the medical industry’s best defense—statins—has only managed symptoms and slowed progression.
Cholrem Pty Ltd has shattered the status quo.
We introduce CAVADEX®, a groundbreaking, scientifically validated therapy that doesn't just treat heart disease—it reverses it.
Validated by a landmark peer-reviewed study published in Cardiology Research and Cardiovascular Medicine (August 2025), CAVADEX® actively dissolves arterial plaque and dangerous cholesterol crystals at the source.
"It's the greatest advance that we have had in cardiovascular pharmacology... since the statins came on the scene." — Professor Laurie Howes, MB BS PhD FRACP FCSANZ (40+ years in Cardiovascular Pharmacology)
A De-Risked Pathway to a Trillion-Dollar Market
This is not a typical early-stage biotech investment. Cholrem is not navigating years of R&D uncertainty. We are a revenue-generating company with a proven product, positioned for exponential growth.
• Proven Human Efficacy: Real-world data and pilot studies demonstrate a remarkable 92% success rate in plaque regression.
• Established Revenue: CAVADEX® has been in production and selling worldwide for over five years.
• Safety Assured: The active ingredient is already FDA-approved (GRAS) with a long-established, non-toxic safety profile.
• Immediate Scalability: Robust, proven manufacturing infrastructure capable of immediately scaling to $25 Million USD in weekly revenue from a single site.
The Catalyst: Formal Clinical Trials
We are at a critical inflection point. We are seeking strategic capital to initiate accelerated clinical trials. The final step to validate our extensive real-world evidence and unlock global market dominance.
These aren’t just any trials, we are going for the Holy Grail of trials. Calcium scores are the leading indicator of heart disease and, until now, have been considered irreversible. No existing therapy can reduce them. We will show calcium scores plummeting within 3 months. We know this because we are seeing it every day from customers using Cavadex.
The commencement of these 3 month trials, scheduled for early November 2025, will serve as a massive commercial catalyst.
Given the proven efficacy and the scale of the addressable market (capturing just 10% of the U.S. market projects revenues exceeding $3.15 billion USD per MONTH!), we project this milestone will elevate Cholrem to a billion-dollar valuation.
The Opportunity
We are offering equity in Cholrem Pty Ltd for this pivotal, limited funding round.
$100,000 per 1% share. Limited round up to $2 million (20% equity) to fund trials and ignite global dominance.
This is a rare opportunity to generate exceptional returns while funding the most significant revolution in cardiovascular health in a generation.
Own a substantial equity share in a potentially multibillion-dollar company.
Request the Business Brief and scientific documentation today.
Visit: www.cholrem.com
Contact: Kyle Hodgetts,
Founder & CEO
会员专区
我要咨询
请使用英文发送留言
* 您的姓名
▼
* 手机号码
* 电子邮箱
留言详情
所有广告信息均由卖家或其代表提供。我们不对信息的准确性、完整性或真实性进行核实，也不提供任何保证或担保。任何因此而产生的纠纷、索赔或决定，均应由买卖双方自行承担和解决。了解更多 如何避免诈骗。